FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Comp Orthop Traumatol / Inflammatory effects of autologous, genetically modified aut...
Veterinary and comparative orthopaedics and traumatology : V.C.O.T2013; 26(6); 453-460; doi: 10.3415/VCOT-13-01-0008

Inflammatory effects of autologous, genetically modified autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses.

Abstract: To compare the clinical and inflammatory joint responses to intra-articular injection of bone marrow-derived mesenchymal stem cells (MSC) including autologous, genetically modified autologous, allogeneic, or xenogeneic cells in horses. Methods: Six five-year-old Thoroughbred mares had one fetlock joint injected with Gey's balanced salt solution as the vehicle control. Each fetlock joint of each horse was subsequently injected with 15 million MSC from the described MSC groups, and were assessed for 28 days for clinical and inflammatory parameters representing synovitis, joint swelling, and pain. Results: There were not any significant differences between autologous and genetically modified autologous MSC for synovial fluid total nucleated cell count, total protein, interleukin (IL)-6, IL-10, fetlock circumference, oedema score, pain-free range-of-motion, and soluble gene products that were detected for at least two days. Allogeneic and xenogeneic MSC produced a greater increase in peak of inflammation at 24 hours than either autologous MSC group. Conclusions: Genetically engineered MSC can act as vehicles to deliver gene products to the joint; further investigation into the therapeutic potential of this cell therapy is warranted. Intra-articular MSC injection resulted in a moderate acute inflammatory joint response that was greater for allogeneic and xenogeneic MSC than autologous MSC. Clinical management of this response may minimize this effect.
Get Full Text
Publication Date: 2013-10-01 PubMed ID: 24080668DOI: 10.3415/VCOT-13-01-0008Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Controlled Clinical Trial
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research compared the effects of injecting different types of mesenchymal stem cells (MSCs) – specifically autologous (from the same individual), genetically modified autologous, allogeneic (from a different individual of the same species), and xenogeneic (from a different species) – into horse joints. They found that the inflammation response was greater when using allogeneic and xenogeneic MSCs, and suggest further research into the therapeutic potential of genetically engineered MSCs.

Research Design and Methodology

  • The subjects of this study were six Thoroughbred mares (female horses), all five years old. The selection of a single breed and age group helped to establish a controlled environment, minimizing potential age or breed-specific variations.
  • The researchers injected one fetlock joint (a joint located in the horse’s leg) with Gey’s balanced salt solution as a control measure, to compare the effects of the different stem cell types.
  • Different categories of MSCs were injected into each horse’s fetlock joint, and the horses were monitored for 28 days for various clinical and inflammatory parameters, which provide indicators of inflammation, swelling, and pain in the joint.

Study Findings

  • As per the results, no significant differences were observed between the effects of autologous and genetically modified autologous MSCs, suggesting that the genetic modification didn’t notably alter the cells’ impact on inflammation or swelling.
  • Allogeneic and xenogeneic MSCs produced an noticeably increased inflammatory response 24 hours after injection compared to either autologous MSC group.
  • Gene products were also detected up to two days post-injection in the joints where genetically engineered MSCs were used, indicating that these can be used to deliver gene products to a targeted area.

Conclusions and Implications

  • The researchers concluded that genetically engineered MSCs show promise as a means of delivering gene products to targeted areas. If they can effectively reduce inflammation and pain, they may offer a potential therapy for conditions affecting the joints.
  • However, this study found that using allogeneic and xenogeneic MSCs induced a greater inflammatory response, which has implications for their use in clinical practice. Strategies to manage this response would be necessary to minimize potential adverse effects.

Cite This Article

APA
Pigott JH, Ishihara A, Wellman ML, Russell DS, Bertone AL. (2013). Inflammatory effects of autologous, genetically modified autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses. Vet Comp Orthop Traumatol, 26(6), 453-460. https://doi.org/10.3415/VCOT-13-01-0008

Publication

Veterinary and comparative orthopaedics and traumatology : V.C.O.T
ISSN: 2567-6911
NlmUniqueID: 8906319
Country: Germany
Language: English
Volume: 26
Issue: 6
Pages: 453-460

Researcher Affiliations

Pigott, J H
  • Dr. Alicia L. Bertone, DVM, PhD, Department of Veterinary Clinical Sciences, The Ohio State University, 380 VMAB, 1900 Coffey Rd, Columbus, OH 43210, United States, Phone: +1 614 292 6661, Fax: +1 614 688 5642, E-mail: bertone.1@osu.edu.
Ishihara, A
    Wellman, M L
      Russell, D S
        Bertone, A L

          MeSH Terms

          • Animals
          • Bone Morphogenetic Protein 2 / genetics
          • Bone Morphogenetic Protein 2 / metabolism
          • Female
          • Gene Expression Regulation
          • Genetic Engineering
          • Horse Diseases / therapy
          • Horses
          • Inflammation / etiology
          • Inflammation / veterinary
          • Injections, Intra-Articular
          • Mesenchymal Stem Cell Transplantation / adverse effects
          • Mesenchymal Stem Cell Transplantation / methods
          • Mesenchymal Stem Cell Transplantation / veterinary
          • Mesenchymal Stem Cells / classification
          • Osteoarthritis / therapy
          • Osteoarthritis / veterinary
          • Synovial Fluid / chemistry
          • Synovial Fluid / cytology

          Citations

          This article has been cited 21 times.
          1. Fu Y, Cui S, Zhou Y, Qiu L. Dental Pulp Stem Cell-Derived Exosomes Alleviate Mice Knee Osteoarthritis by Inhibiting TRPV4-Mediated Osteoclast Activation.. Int J Mol Sci 2023 Mar 3;24(5).
            doi: 10.3390/ijms24054926pubmed: 36902356google scholar: lookup
          2. Pezzanite LM, Chow L, Griffenhagen GM, Bass L, Goodrich LR, Impastato R, Dow S. Distinct differences in immunological properties of equine orthobiologics revealed by functional and transcriptomic analysis using an activated macrophage readout system.. Front Vet Sci 2023;10:1109473.
            doi: 10.3389/fvets.2023.1109473pubmed: 36876001google scholar: lookup
          3. Mund SJK, MacPhee DJ, Campbell J, Honaramooz A, Wobeser B, Barber SM. Macroscopic, Histologic, and Immunomodulatory Response of Limb Wounds Following Intravenous Allogeneic Cord Blood-Derived Multipotent Mesenchymal Stromal Cell Therapy in Horses.. Cells 2021 Nov 1;10(11).
            doi: 10.3390/cells10112972pubmed: 34831196google scholar: lookup
          4. Ribitsch I, Oreff GL, Jenner F. Regenerative Medicine for Equine Musculoskeletal Diseases.. Animals (Basel) 2021 Jan 19;11(1).
            doi: 10.3390/ani11010234pubmed: 33477808google scholar: lookup
          5. Magri C, Schramme M, Febre M, Cauvin E, Labadie F, Saulnier N, François I, Lechartier A, Aebischer D, Moncelet AS, Maddens S. Comparison of efficacy and safety of single versus repeated intra-articular injection of allogeneic neonatal mesenchymal stem cells for treatment of osteoarthritis of the metacarpophalangeal/metatarsophalangeal joint in horses: A clinical pilot study.. PLoS One 2019;14(8):e0221317.
            doi: 10.1371/journal.pone.0221317pubmed: 31465445google scholar: lookup
          6. Daems R, Van Hecke L, Schwarzkopf I, Depuydt E, Broeckx SY, David M, Beerts C, Vandekerckhove P, Spaas JH. A Feasibility Study on the Use of Equine Chondrogenic Induced Mesenchymal Stem Cells as a Treatment for Natural Occurring Osteoarthritis in Dogs.. Stem Cells Int 2019;2019:4587594.
            doi: 10.1155/2019/4587594pubmed: 31281373google scholar: lookup
          7. Bertoni L, Branly T, Jacquet S, Desancé M, Desquilbet L, Rivory P, Hartmann DJ, Denoix JM, Audigié F, Galéra P, Demoor M. Intra-Articular Injection of 2 Different Dosages of Autologous and Allogeneic Bone Marrow- and Umbilical Cord-Derived Mesenchymal Stem Cells Triggers a Variable Inflammatory Response of the Fetlock Joint on 12 Sound Experimental Horses.. Stem Cells Int 2019;2019:9431894.
            doi: 10.1155/2019/9431894pubmed: 31191689google scholar: lookup
          8. Smit Y, Marais HJ, Thompson PN, Mahne AT, Goddard A. Clinical findings, synovial fluid cytology and growth factor concentrations after intra-articular use of a platelet-rich product in horses with osteoarthritis.. J S Afr Vet Assoc 2019 May 23;90(0):e1-e9.
            doi: 10.4102/jsava.v90i0.1721pubmed: 31170778google scholar: lookup
          9. Kornicka K, Geburek F, Röcken M, Marycz K. Stem Cells in Equine Veterinary Practice-Current Trends, Risks, and Perspectives.. J Clin Med 2019 May 14;8(5).
            doi: 10.3390/jcm8050675pubmed: 31091732google scholar: lookup
          10. Ball AN, Phillips JN, McIlwraith CW, Kawcak CE, Samulski RJ, Goodrich LR. Genetic modification of scAAV-equine-BMP-2 transduced bone-marrow-derived mesenchymal stem cells before and after cryopreservation: An "off-the-shelf" option for fracture repair.. J Orthop Res 2019 Jun;37(6):1310-1317.
            doi: 10.1002/jor.24209pubmed: 30578639google scholar: lookup
          11. Bogers SH. Cell-Based Therapies for Joint Disease in Veterinary Medicine: What We Have Learned and What We Need to Know.. Front Vet Sci 2018;5:70.
            doi: 10.3389/fvets.2018.00070pubmed: 29713634google scholar: lookup
          12. Berglund AK, Fortier LA, Antczak DF, Schnabel LV. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells.. Stem Cell Res Ther 2017 Dec 22;8(1):288.
            doi: 10.1186/s13287-017-0742-8pubmed: 29273086google scholar: lookup
          13. Taroni M, Cabon Q, Fèbre M, Cachon T, Saulnier N, Carozzo C, Maddens S, Labadie F, Robert C, Viguier E. Evaluation of the Effect of a Single Intra-articular Injection of Allogeneic Neonatal Mesenchymal Stromal Cells Compared to Oral Non-Steroidal Anti-inflammatory Treatment on the Postoperative Musculoskeletal Status and Gait of Dogs over a 6-Month Period after Tibial Plateau Leveling Osteotomy: A Pilot Study.. Front Vet Sci 2017;4:83.
            doi: 10.3389/fvets.2017.00083pubmed: 28642867google scholar: lookup
          14. Bertone AL, Reisbig NA, Kilborne AH, Kaido M, Salmanzadeh N, Lovasz R, Sizemore JL, Scheuermann L, Kopp RJ, Zekas LJ, Brokken MT. Equine Dental Pulp Connective Tissue Particles Reduced Lameness in Horses in a Controlled Clinical Trial.. Front Vet Sci 2017;4:31.
            doi: 10.3389/fvets.2017.00031pubmed: 28344975google scholar: lookup
          15. Berglund AK, Schnabel LV. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.. Equine Vet J 2017 Jul;49(4):539-544.
            doi: 10.1111/evj.12647pubmed: 27862236google scholar: lookup
          16. Dias MC, Landim-Alvarenga FD, de Moraes CN, da Costa LD, Geraldini CM, de Vasconcelos Machado VM, Maia L. Intramuscular Transplantation of Allogeneic Mesenchymal Stromal Cells Derived from Equine Umbilical Cord.. Int J Stem Cells 2016 Nov 30;9(2):239-249.
            doi: 10.15283/ijsc16011pubmed: 27572709google scholar: lookup
          17. Williams LB, Co C, Koenig JB, Tse C, Lindsay E, Koch TG. Response to Intravenous Allogeneic Equine Cord Blood-Derived Mesenchymal Stromal Cells Administered from Chilled or Frozen State in Serum and Protein-Free Media.. Front Vet Sci 2016;3:56.
            doi: 10.3389/fvets.2016.00056pubmed: 27500136google scholar: lookup
          18. Ardanaz N, Vázquez FJ, Romero A, Remacha AR, Barrachina L, Sanz A, Ranera B, Vitoria A, Albareda J, Prades M, Zaragoza P, Martín-Burriel I, Rodellar C. Inflammatory response to the administration of mesenchymal stem cells in an equine experimental model: effect of autologous, and single and repeat doses of pooled allogeneic cells in healthy joints.. BMC Vet Res 2016 Mar 31;12:65.
            doi: 10.1186/s12917-016-0692-xpubmed: 27029614google scholar: lookup
          19. Espina M, Jülke H, Brehm W, Ribitsch I, Winter K, Delling U. Evaluation of transport conditions for autologous bone marrow-derived mesenchymal stromal cells for therapeutic application in horses.. PeerJ 2016;4:e1773.
            doi: 10.7717/peerj.1773pubmed: 27019778google scholar: lookup
          20. Vilar JM, Batista M, Morales M, Santana A, Cuervo B, Rubio M, Cugat R, Sopena J, Carrillo JM. Assessment of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells in osteoarthritic dogs using a double blinded force platform analysis.. BMC Vet Res 2014 Jul 1;10:143.
            doi: 10.1186/1746-6148-10-143pubmed: 24984756google scholar: lookup
          21. Phinney DG, Isakova IA. Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.. Brain Res 2014 Jul 21;1573:92-107.
            doi: 10.1016/j.brainres.2014.05.029pubmed: 24858930google scholar: lookup
          Subscribe to our newsletter
          Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.